ParkinsonCanadaV1, PubMed, Curation, bibRecord, 001072

Therapeutic approaches to inflammation in neurodegenerative disease.

Identifieur interne : 001072 ( PubMed/Curation ); précédent : 001071; suivant : 001073

Therapeutic approaches to inflammation in neurodegenerative disease.

Auteurs : Andis Klegeris [Canada] ; Edith G. Mcgeer ; Patrick L. Mcgeer

Source :

Current opinion in neurology [ 1350-7540 ] ; 2007.

RBID : pubmed:17495632

English descriptors

KwdEn :
- Brain (drug effects), Brain (immunology), Brain (physiopathology), Encephalitis (drug therapy), Encephalitis (immunology), Encephalitis (physiopathology), Gliosis (drug therapy), Gliosis (immunology), Gliosis (physiopathology), Humans, Immunologic Factors (pharmacology), Immunologic Factors (therapeutic use), Immunotherapy (methods), Immunotherapy (trends), Microglia (drug effects), Microglia (immunology), Parkinson Disease (drug therapy), Parkinson Disease (immunology), Parkinson Disease (physiopathology), Receptors, Cytokine (drug effects), Receptors, Cytokine (immunology), alpha-Synuclein (immunology).
MESH :
- chemical , drug effects : Receptors, Cytokine.
- chemical , immunology : Receptors, Cytokine, alpha-Synuclein.
- chemical , pharmacology : Immunologic Factors.
- drug effects : Brain, Microglia.
- drug therapy : Encephalitis, Gliosis, Parkinson Disease.
- immunology : Brain, Encephalitis, Gliosis, Microglia, Parkinson Disease.
- methods : Immunotherapy.
- physiopathology : Brain, Encephalitis, Gliosis, Parkinson Disease.
- chemical , therapeutic use : Immunologic Factors.
- trends : Immunotherapy.
- Humans.

Abstract

According to the neuroinflammatory hypothesis of neurodegenerative diseases, drugs with an anti-inflammatory mode of action should slow the disease progression. Here we review recent advances in our understanding of one such disorder, Parkinson's disease, in which anti-inflammatory drugs are now becoming a new therapeutic focus.

DOI: 10.1097/WCO.0b013e3280adc943
PubMed: 17495632

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001072

Links to Exploration step

pubmed:17495632

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic approaches to inflammation in neurodegenerative disease.</title>
<author><name sortKey="Klegeris, Andis" sort="Klegeris, Andis" uniqKey="Klegeris A" first="Andis" last="Klegeris">Andis Klegeris</name>
<affiliation wicri:level="1"><nlm:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada. aklegeri@interchange.ubc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Edith G" sort="Mcgeer, Edith G" uniqKey="Mcgeer E" first="Edith G" last="Mcgeer">Edith G. Mcgeer</name>
</author>
<author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17495632</idno>
<idno type="pmid">17495632</idno>
<idno type="doi">10.1097/WCO.0b013e3280adc943</idno>
<idno type="wicri:Area/PubMed/Corpus">001072</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001072</idno>
<idno type="wicri:Area/PubMed/Curation">001072</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001072</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic approaches to inflammation in neurodegenerative disease.</title>
<author><name sortKey="Klegeris, Andis" sort="Klegeris, Andis" uniqKey="Klegeris A" first="Andis" last="Klegeris">Andis Klegeris</name>
<affiliation wicri:level="1"><nlm:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada. aklegeri@interchange.ubc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Edith G" sort="Mcgeer, Edith G" uniqKey="Mcgeer E" first="Edith G" last="Mcgeer">Edith G. Mcgeer</name>
</author>
<author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name>
</author>
</analytic>
<series><title level="j">Current opinion in neurology</title>
<idno type="ISSN">1350-7540</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brain (drug effects)</term>
<term>Brain (immunology)</term>
<term>Brain (physiopathology)</term>
<term>Encephalitis (drug therapy)</term>
<term>Encephalitis (immunology)</term>
<term>Encephalitis (physiopathology)</term>
<term>Gliosis (drug therapy)</term>
<term>Gliosis (immunology)</term>
<term>Gliosis (physiopathology)</term>
<term>Humans</term>
<term>Immunologic Factors (pharmacology)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Immunotherapy (methods)</term>
<term>Immunotherapy (trends)</term>
<term>Microglia (drug effects)</term>
<term>Microglia (immunology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (immunology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Receptors, Cytokine (drug effects)</term>
<term>Receptors, Cytokine (immunology)</term>
<term>alpha-Synuclein (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Cytokine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Receptors, Cytokine</term>
<term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
<term>Microglia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Encephalitis</term>
<term>Gliosis</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Brain</term>
<term>Encephalitis</term>
<term>Gliosis</term>
<term>Microglia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term>
<term>Encephalitis</term>
<term>Gliosis</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Immunotherapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">According to the neuroinflammatory hypothesis of neurodegenerative diseases, drugs with an anti-inflammatory mode of action should slow the disease progression. Here we review recent advances in our understanding of one such disorder, Parkinson's disease, in which anti-inflammatory drugs are now becoming a new therapeutic focus.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17495632</PMID>
<DateCreated><Year>2007</Year>
<Month>05</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>07</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>01</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1350-7540</ISSN>
<JournalIssue CitedMedium="Print"><Volume>20</Volume>
<Issue>3</Issue>
<PubDate><Year>2007</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Current opinion in neurology</Title>
<ISOAbbreviation>Curr. Opin. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Therapeutic approaches to inflammation in neurodegenerative disease.</ArticleTitle>
<Pagination><MedlinePgn>351-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">According to the neuroinflammatory hypothesis of neurodegenerative diseases, drugs with an anti-inflammatory mode of action should slow the disease progression. Here we review recent advances in our understanding of one such disorder, Parkinson's disease, in which anti-inflammatory drugs are now becoming a new therapeutic focus.</AbstractText>
<AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">The involvement of inflammatory mechanisms in Parkinson's disease has been revealed through in-vitro and in-vivo experimental studies supported by pathological and epidemiological findings. Several of the demonstrated inflammatory mechanisms are shared by other neurodegenerative disorders but some Parkinson's disease-specific mechanisms have also emerged. These include inflammatory stimulation by interaction of alpha-synuclein with microglia and astrocytes and a suppressive action by nonsteroidal anti-inflammatory drugs on dopamine quinone formation.</AbstractText>
<AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">It can be anticipated that a more detailed understanding of neuroinflammatory mechanisms in Parkinson's disease will lead to new cellular and molecular targets, which may, in turn, permit design of Parkinson's disease modifying drugs. Future treatment may involve combination therapies with drugs directed at both inflammatory and non-inflammatory mechanisms.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klegeris</LastName>
<ForeName>Andis</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada. aklegeri@interchange.ubc.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McGeer</LastName>
<ForeName>Edith G</ForeName>
<Initials>EG</Initials>
</Author>
<Author ValidYN="Y"><LastName>McGeer</LastName>
<ForeName>Patrick L</ForeName>
<Initials>PL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Curr Opin Neurol</MedlineTA>
<NlmUniqueID>9319162</NlmUniqueID>
<ISSNLinking>1350-7540</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018121">Receptors, Cytokine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018121" MajorTopicYN="N">Receptors, Cytokine</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>65</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>5</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>7</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>5</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17495632</ArticleId>
<ArticleId IdType="doi">10.1097/WCO.0b013e3280adc943</ArticleId>
<ArticleId IdType="pii">00019052-200706000-00018</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001072 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001072 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:17495632
   |texte=   Therapeutic approaches to inflammation in neurodegenerative disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:17495632" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Therapeutic approaches to inflammation in neurodegenerative disease.

Therapeutic approaches to inflammation in neurodegenerative disease.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki